2003 Drug Development Trials Vaccine 
NIH Director's Blog: Drug Development
MAY 21, 2020
This structural information helps to clarify the precise biochemistry of the complex interaction between SARS-CoV-2 and the antibody, providing a much-needed guide for the rational design of targeted drugs and vaccines. In the U.S. Collins FS, Stoffels P. 2020 May 18.
NIH Director's Blog: Drug Development
MARCH 18, 2021
He uses these fundamental insights to guide the design of vaccines and therapeutics, including promising monoclonal antibodies. He’s also a member of the international research team that identified a human antibody, called S309, from a person who’d been infected with SARS in 2003.
The Pharma Data
APRIL 25, 2021
Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. The overall safety profile of nirsevimab in the trial remains consistent with previously reported results. Lurie Children’s Hospital of Chicago, Illinois, US and primary investigator of the MELODY Phase III trial.
Expert insights. Personalized for you.
52 
Let's personalize your content